This 3D Tumor Models Standards working group was conceptualized from the realization of the importance of developing in vitro 3D tumor models that mimic the in vivo tumor physiology for more efficient drug discovery for cancer. Our inaugural meeting at the AACR in April 2017 brought together key opinion leaders in academia, industry and government to establish guidelines that we believe are critical to establish 3D tumor models as a highly predictive platform of assays for therapeutic drug development. The outcome of that meeting resulted in action items and a broader engagement of the 3D community with respect to setting standards for both screening and validation of 3D models as it pertains to mechanistic intervention and therapeutic indications. The recommendations/guidelines put together by this group will hopefully be published and disseminated to the broader research community in an effort to leverage the best information gathered by from the multiple 3D tumor models being developed for drug development.
For more information on this event, please contact Madhu Lal, NIH/NCATS at firstname.lastname@example.org.
The asset you are trying to access is locked. Please enter your access key to unlock.